• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.50 EUR-0.60 %10/7 9:26
5,739 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.60 %
+1.64 %
-5.97 %
-76.32 %
-75.12 %
-79.26 %
-82.92 %
-88.27 %
-85.13 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
113.14M EUR
Turnover
36.04K EUR
P/E (adj.) (26e)
-4.81
EV/EBIT (adj.) (26e)
-5.55
P/B (26e)
86.16
EV/S (26e)
26,348.03
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
And the article: Bexmarilimab and azacitidine: promise for immunotherapy in myelodysplastic syndrome? - Keiffer - Annals of Blood
yesterday
by Tuttiruu
30
That 3.73 billion by 2031 figure implies that it excludes, for example, anti-PD-1 drugs; pembro (pembrolizumab) alone has sold about 30 billion. It has apparently only calculated macrophage modulators, such as Bex (bexmarilimab) and others, cytokines, vascular growth factors (which...
yesterday
by Vino Pino
18
Relating to an earlier study: “Macrophage sensitivity to reprogramming by bexmarilimab is shaped by the tumor microenvironment” The study did not primarily measure clinical efficacy, such as survival or response rate, but asked: What does bexmarilimab do to macrophages and the tumor...
7/6/2026, 8:56 AM
by Makkispekkis1
17
Light summer reading including topics such as the tumor microenvironment and a small section on modulating the tumor immune microenvironment. Bex is mentioned in section 6.5: The humanized antibody bexmarilimab, which targets Clever-1, enhances IFN-γ signaling activity in TAMs (tumor...
7/7/2026, 3:33 PM
by J
16
There have been several examples along the way where companies know how to sell expertise and science at a reasonable price, to the benefit of everyone involved. Then there are those promising firms that would rather be driven to the brink of bankruptcy than let a buyer get them ...
7/7/2026, 11:50 AM
by Raikku
16
The Myriczin/Novartis drug aims to be some kind of “pan-cancer” treatment that works for many different types of cancer, apparently specifically targeting solid tumors. However, the drug is only just moving from the preclinical to the clinical trial phase, so there are still years...
7/6/2026, 2:58 PM
by Sebastian Soderholm
16
Let’s talk a bit about money: Tumor Microenvironment Modulation Market to Hit USD 3.73 Billion by 2031 with a 7.4% CAGR - Key Trends and Insights Yahoo Finance Tumor Microenvironment Modulation Market to Hit USD 3.73 Billion by 2031 with... The tumor microenvironment modulation market...
7/8/2026, 4:07 AM
by Kulkuri
13
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Regulatory press release2026-07-01 12:00

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release2026-06-22 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-17 15:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-06-17 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release2026-06-16 14:58

Redeye: Faron Pharmaceuticals: Matured BEXMAB data from EHA and BEXERA update

Faron Pharmaceuticals
Faron's BEXMAB update provided additional information on response duration
Analyst Comment2026-06-16 08:15 by
Antti Siltanen

Faron's BEXMAB update provided additional information on response duration

According to the company, the Phase 2b BEXERA trial will start in H2'26.

Faron Pharmaceuticals
Regulatory press release2026-06-15 17:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron Pharmaceuticals EHA 2026
Webcast2026-06-15 15:00

Faron Pharmaceuticals EHA 2026

Faron Pharmaceuticals
Press release2026-06-15 08:00

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:05

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:00

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

Faron Pharmaceuticals
Regulatory press release2026-06-10 18:45

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-08 18:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-05 12:50

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

Faron Pharmaceuticals
Regulatory press release2026-06-04 14:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-03 13:00

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals
Regulatory press release2026-06-03 08:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals
Regulatory press release2026-06-01 14:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-05-28 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-05-28 14:35

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Faron Pharmaceuticals